RIGL · Rigel Pharmaceuticals Inc · Insider Trading

The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2020, subject to the Reporting Person's continuous service to the Issuer through each such period.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the Issuer through each such period.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

The shares of common stock subject to the option vested monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer through each such period.

Includes 500 shares acquired under the Issuer's stock purchase plan.

Includes 500 shares acquired under the Issuer's stock purchase plan.

Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.

Includes 500 shares acquired under the Issuer's stock purchase plan.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027.

Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.

The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.

The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.

The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.

The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

The shares vested monthly over twelve (12) months from the grant date of May 11, 2016.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.